Welcome to our dedicated page for Savara news (Ticker: SVRA), a resource for investors and traders seeking the latest updates and insights on Savara stock.
Savara Inc. develops therapies for rare respiratory diseases, with a lead program in molgramostim inhalation solution, conditionally named MOLBREEVI, for autoimmune pulmonary alveolar proteinosis. Molgramostim is a recombinant human GM-CSF delivered through an investigational eFlow Nebulizer System developed for inhalation of the large-molecule therapy.
Recurring company developments include clinical data from the IMPALA-2 program, regulatory submissions and agency-review updates in the U.S., Europe and the U.K., financial results, financing arrangements, equity inducement grants and investor conference participation. Savara's updates also note that MOLBREEVI is not approved in any indication.
Savara has announced inducement awards for a new employee hired on May 14, 2024. The awards include options to purchase 15,000 shares of common stock and 2,500 restricted stock units (RSUs). The options, priced at $4.81 per share, align with the closing trading price on the grant date and have a 10-year term. The options vest quarterly over four years, while the RSUs vest in full after two years. These grants are made under Savara's 2021 Inducement Equity Incentive Plan according to NASDAQ Rule 5635(c)(4).
Savara Inc. (Nasdaq: SVRA) reported their first-quarter financial results for 2024, showcasing a net loss of $20.3 million compared to $10.6 million in 2023. The company remains focused on the Phase 3 IMPALA-2 trial evaluating molgramostim for autoimmune Pulmonary Alveolar Proteinosis, with top-line results expected by 2Q 2024. Savara anticipates submitting a Biologics License Application in 1H 2025 and is well-capitalized with $143 million in cash into 2026.
Savara Inc. (SVRA) will be presenting at the Citizens JMP Life Sciences Conference, with a live webcast available on their website. The event is scheduled for May 14, 2024, at 6:00am PT/9:00am ET, focusing on rare respiratory diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.